---
title: EHA 2023 Breakfast Briefings - June 11, 2023
---

[![CE Concepts Healthcare Education](https://info.ceconcepts.com/hs-fs/hubfs/CEC/_Brand%20Assets/CEC-Logo_Horizontal_Color_500x140.png?width=500&height=140&name=CEC-Logo_Horizontal_Color_500x140.png "CE Concepts Healthcare Education")](http://ceconcepts.com)

Open main menu Close main menu

- [June 8, 2023](https://info.ceconcepts.com/eha-2023-breakfast-briefings-june-8-2023)
- [June 9, 2023](https://info.ceconcepts.com/eha-2023-breakfast-briefings-june-9-2023)
- [June 10, 2023](https://info.ceconcepts.com/eha-2023-breakfast-briefings-june-10-2023)
- [June 11, 2023](https://info.ceconcepts.com/eha-2023-breakfast-briefings-june-11-2023)

# 2023 Breakfast Briefings June 11th, 2023

Supported through an independent educational grant from Merck.

<iframe data-hsv-src="https://play.hubspotvideo.com/v/2788055/id/119269678762?play_button_color=ffffff" referrerpolicy="origin" sandbox="allow-forms allow-scripts allow-same-origin allow-popups" allow="autoplay; fullscreen;" style="position: absolute !important; width: 100% !important; height: 100% !important; left: 0; top: 0; border: 0 none; pointer-events: initial" title="HubSpot Video" loading="lazy" data-hsv-id="119269678762" data-hsv-play-button-color="ffffff" data-hsv-width="1280" data-hsv-height="720" data-hsv-full-width="false"></iframe>

---

## Abstract Info

##### Final 7-Year Follow Up and Retreatment Substudy Analysis of Murano: Venetoclax-Rituximab (VenR)-Treated Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL)

Number: S201

Author: Arnon Kater

[Abstract (pdf)](https://cpenow.sharepoint.com/:b:/s/CEConceptsGeneral/EfcwnIQSB9xGnzztHmh7ciIBlYJxEcoip0KrKgxD27z-jg?e=AnllIO)

##### Ibrutinib versus Placebo in Patients with Asymptomatic, Treatment-Naïve Early Stage Chronic Lymphocytic Leukemia (CLL): Final Results of the Phase 3, Double-Blind, Placebo-Controlled CLL12 Trial (Petra Langerbeins)

Number: S200

Author: P Langerbeins

[Abstract (pdf)](https://cpenow.sharepoint.com/:b:/s/CEConceptsGeneral/EWYGeHKtledIn_DGEzlqe8IBlSuldc2kEeCn0h9s7uwg2w?e=4Jykac )

### Moderator

#### ![Moderator-Ghia](https://info.ceconcepts.com/hs-fs/hubfs/Moderator-Ghia.png?width=177&height=179&name=Moderator-Ghia.png)

#### Paolo Ghia, MD, PhD

Full Professor, Medical Oncology

Director, Strategic Research Program on CLL

Deputy Chairman, Experimental Oncology Division Head, B-Cell

Neoplasia Unit

Università Vita-Salute San Raffaele

RCCS Ospedale San Raffaele

Milano, Italy 

#### About

- Menu Item One
- Menu Item Two
- Menu Item Three

#### Services

- Menu Item One
- Menu Item Two
- Menu Item Three

#### News

- Menu Item One
- Menu Item Two
- Menu Item Three

Follow us on Facebook Follow us on LinkedIn Follow us on Twitter Follow us on Instagram

```json
{
  "@context" : "https://schema.org",
  "@type" : "VideoObject",
  "contentUrl" : "https://2788055.fs1.hubspotusercontent-na1.net/hubfs/2788055/CEC/bb-036_june_11%20(Original).mp4",
  "dateModified" : "2023-06-15T02:15:18.646Z",
  "duration" : "PT5M3.52S",
  "height" : 720,
  "name" : "bb-036_june_11 (Original)",
  "thumbnailUrl" : "https://2788055.fs1.hubspotusercontent-na1.net/hubfs/2788055/CEC/bb-036_june_11%20(Original).mp4/medium.jpg",
  "uploadDate" : "2023-06-07T19:37:47.954Z",
  "width" : 1280
}
```